Yahoo
NasdaqCM - Nasdaq Real Time Price USD

CNS Pharmaceuticals, Inc. (CNSP)

5.89 +0.11 (+1.94%)
As of 10:51:41 AM EDT. Market Open.
Chart Range Bar
Loading chart for CNSP
  • Previous Close 5.78
  • Open 5.77
  • Bid 4.03 x 200
  • Ask 7.61 x 200
  • Day's Range 5.77 - 5.89
  • 52 Week Range 1.90 - 10.59
  • Volume 1,450
  • Avg. Volume 11,352
  • Market Cap (intraday) 8.611M
  • Beta (5Y Monthly) 0.98
  • PE Ratio (TTM) --
  • EPS (TTM) -15.39
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 10.00

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.

cnspharma.com

8

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CNSP
12.23%
S&P 500 (^GSPC)
11.66%

1-Year Return

CNSP
4.97%
S&P 500 (^GSPC)
18.32%

3-Year Return

CNSP
99.99%
S&P 500 (^GSPC)
69.27%

5-Year Return

CNSP
100.00%
S&P 500 (^GSPC)
68.96%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -4.94M
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-4M
-2M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

10.00
10.00 Average
5.89 Current
10.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/12/2025
Analyst Maxim Group
Rating Action Upgrade
Rating Buy
Price Action Announces
Price Target 20

Statistics

View More

Valuation Measures

Annual
As of 8/27/2026
  • Market Cap

    8.06M

  • Enterprise Value

    5.34M

  • Trailing P/E

    0.00

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.44

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -58.01%

  • Return on Equity (ttm)

    -106.62%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -16.7M

  • Diluted EPS (ttm)

    -15.39

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    19.98M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -7.94M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

5.89 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: